Dr. Yaojun Zhang is a professor of Department of Liver Surgery in Sun Yat-sen University Cancer Center (SYSUCC). Dr. Zhang obtained his Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University, P. R. China in 2002 and 2014, respectively. After his graduation form medical university, Dr. Zhang started his clinical training at Sun Yat-sen University Cancer Center (SYSUCC), five years for resident training and five years for attending training. His specialist is multi-disciplinary treatment for Hepatocellular Carcinoma (HCC), including surgical resection, local ablation therapy, transcatheter arterial chemoembolization (TACE), systemic chemotherapy, macular target therapy, and so on. Importantly Dr. Zhang is experienced in radiofrequency ablation and laparscopic liver resection for liver tumors.

Research Support
1.MD Anderson Cancer Center Sister Institution Network Fund (SINF): Novel point-of-care tool to predict response to sorafenib in hepateocellular carcinoma, 2015-2017, PI for Chinese institution

2.The National Natural Science Foundation of China (NSFC): The relationship and mechanism of intestinal microflora-dependent  metabolitic   choline-  trimethylamine oxide and nonalcoholic fatty liver disease (81472966), 2015-2018, Co-Investigator

3.5010 Program of Sun Yat-Sen University: Re-hepatectomy Versus Radiofrequency ablation combine with transcatheter arterial chemoembolization for recurrent small hepatocellular carcinoma – a prospective randomization control trial, 2013-2013, Co-Investigator

Hepatocellular carcinoma and mini-invasive treatment.

Cancer Center, Sun Yat-sen University 9/2009- 7/2014

Degree: Medical Doctor Cancer Center, 

Sun Yat-sen University 9/2002- 7/2005

Degree: Medical Master 

Sun Yat-sen University 9/1997- 7/2002

Degree: Medical Bachelor

1. Zhenwei Peng, Yaojun Zhang, Minshan Chen*, Li Xu, Huihong Liang, Xiaojun Lin, Rongping Guo, Yaqi Zhang, WanYee Lau. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. Journal of Clinical Oncology. 31(4):426-432, 2013. (Co-author)

2. Yaojun Zhang, Zhenwei Peng, Meixian Chen, Furong Liu,  Junting Huang, Li Xu, Yaqi Zhang, Minshan Chen*. Elevated neutrophil to lymphocyte ratio might predict poor prognosis for colorectal liver metastasis after percutaneous radiofrequency ablation. International Journal of Hyperthermia. 28(2):132-140, 2012.

3. Yaojun Zhang, Adam Frampton, Charis Kyriakides, Nagy Habib, Raida Ahmad, Long R Jiao*. Pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: predictors for loco-recurrence and its implications for adjuvant chemoradiotherapy. Journal of Cancer Research and Clinical Oncology. 138(6): 1063-1071, 2012.

4. Yaojun Zhang, Adam E. Frampton, Jack L. Martin, Charis Kyriakides, Panagiotis Vlavianos, Long R Jiao*. 18F-fluorodeoxyglucose positron emission tomography in management of pancreatic cystic tumors. Nuclear Medicine and Biology. 39(7):982-985, 2012.

5. Yaojun Zhang, Jia Huang, Minshan Chen, Long R Jiao*. Preoperative vascular evaluation with computed tomography and magnetic resonance imaging for pancreatic cancer: a meta-analysis. Pancreatology. 12(3):227-233, 2012.

6. Yaojun Zhang, Adam E. Frampton, Patrizia Cohen, Charis Kyriakides, Jan J. Bong, Nagy A. Habib, Duncan R. C. Spalding, Raida Ahmad, Long R. Jiao*. Tumor infiltration in the medial resection margin predicts survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery. 16(10): 1875-1882, 2012.

7. Yaojun Zhang, Huihong Liang, Minshan Chen*, Rongping Guo,  Jinqing Li, Yun Zheng, Yaqi Zhang, WanY. Lau. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology. 2007, 244(2): 599-607.

8. Junting Huang, Yaojun Zhang, Zhenwei Peng, Hengjun Gao, Li Xu, Long R. Jiao, Minshan Chen*. A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy. J Cancer Res Clin Oncol. 2013;139(10):1709-19. (Co-author)

9. Hengjun Gao, Yaojun Zhang, Minshan Chen*, Meixian Chen, Junting Huang, Li Xu, WanYee Lau. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma. Liver Int. 2014, 34(4):612-620. (Co-author)

10. Jia Huang, Yaojun Zhang, Meixian Chen, Junting Huang, Li Xu,  Minsha Chen. Family history of hepatocellulcar carcinoma is not associated with its patients' prognosis after hepatectomy. World J Surg Oncol. 2013, 11(1):280. (Co-author)

11. Jiaqiang Dan, Yaojun Zhang, Zhenwei Peng, Junting Huang, Hengjun Gao, Li Xu, Minshan Chen*. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PLoS ONE. 8(3): e58184. (Co-author)

12. Jiaqiang Dan, Yaojun Zhang, Jungting Huang, Minshan Chen*, Hengjun Gao, Zhenwei Peng, Li Xu, WanYee Lau. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: A retrospective study. European Journal of Surgical Oncology. 2013, 39:865-872. (Co-author)

13. Hengjun Gao, Yaojun Zhang, Huihong Liang, Peng Li, Zhenwei Peng, Xionghao Pang, Minshan Chen*. Radiofrequency ablation does not induce the significant increase of CD4+CD25+Foxp3+ regulatory T cells compared with surgical resection in Hepal-6 tumor model. Arch Immunol Ther Exp (Warsz). 2013, 61(4):333-340. (Co-author)

14. Zhenwei Peng, Yaojun Zhang, Minshan Chen*, Xiaojun Lin, Huihong Liang, Ming Shi.  Radiofrequency ablation as first-line treatment for small solitary hepatocellular carcinoma: long-term results. European Journal of Surgical Oncology. 36(11):1054-1060, 2010. (Co-author)

15. Haiqing Ma, Yaojun Zhang, Qijing Wang, Yongqiang Li, Jia He, Hui Wang, Jiancong Sun, Ke Pan, Minshan Chen*, Jianchan Xia*. Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellulcar carcinoma after radiofrequency ablation. Cancer Biology & Therapy. 9(11):903-907, 2010.  (Co-author)

 

Last Updated: February 2015 by International Office, Sun Yat-sen University Cancer Center